Is zinc-α2-glycoprotein a cardiovascular protective factor for patients undergoing hemodialysis?

Clinica Chimica Acta

Volumn 413, Issue 5-6, 2012, Pages 616-619

  Leal, Viviane O ^a   Lobo, Julie C ^b   Stockler Pinto, Milena B ^b   Farage, Najla E ^c   Abdalla, Dulcinéia S P ^d   Leite Junior, Maurilo ^b   Mafra, Denise ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c RenalCor   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adipokine; Atherosclerosis; Hemodialysis; Inflammation; Zinc 2 glycoprotein

Indexed keywords

ADIPONECTIN; ALPHA2 GLYCOPROTEIN; C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ZINC ALPHA2 GLYCOPROTEIN;

ADULT; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART PROTECTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

CARDIOVASCULAR DISEASES; HUMANS; RENAL DIALYSIS; SEMINAL PLASMA PROTEINS;

EID: 84856224604     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.12.002     Document Type: Article

References (42)

1. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
2. Antuna-Punte B., Feve B., Fellahi S., Bastard J.D. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008, 34:2-11.
3. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
4. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a camp-dependent pathway. Circulation 2000, 102:1296-1301.
5. Awazawa M., Ueki K., Inabe K., et al. Adiponectin enhances insulin sensitivity by increasing hepatic ISR-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab 2011, 13:401-412.
6. Bing C., Mracek T., Gao D., Trayhurn P. Zinc-α2-glycoprotein: an adipokine modulator of body fat mass?. Int J Obes 2010, 34:1559-1565.
7. Burgi W., Schmid K. Preparation and properties of Zn-α2-glycoprotein of normal human plasma. J Biol Chem 1961, 236:1066-1074.
8. Bao Y., Bing C., Hunter L., Jenkins J., Wabitsch M., Trayurhn P. Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SBGS) adipocytes. FEBS Lett 2005, 579:41-47.
9. Bing C., Bao Y., Jenkins J., et al. Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci U S A 2004, 101:2500-2505.
10. Hirai K., Hussey H.J., Barber M.D., Price S.A., Tisdale M.J. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 1998, 58:2359-2365.
11. Gong F.Y., Zhang S.J., Deng J.Y., et al. Zinc-alpha2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. Int J Obes 2009, 33:1023-1030.
12. Sanders P.M., Tisdale M.J. Effect of zinc-α2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue. Cancer Lett 2004, 212:71-81.
13. Mracek T., Gao D., Tzanavari T., et al. Downregulation of zinc-α2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumor necrosis factor-α in adipocytes. J Endocrinol 2010, 204:165-172.
14. Ceperuello-Mallafré V., Naf S., Escoté X., et al. Circulating and adipose tissue gene expression of zinc-α2-glycoprotein in obesity: its relationship with adipokine and lipolytic gene markers in subcutaneous and visceral fat. J Clin Endocrinol Metab 2009, 94:5062-5069.
15. Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am J Physiol Renal Physiol 2006, 290:F262-F272.
16. Kalantar-Zadeh K., Kopple J.D., Humphreys M.H., Block G. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004, 19:1507-1519.
17. Shastri S., Sarnak M.J. Cardiovascular disease and CKD: core curriculum 2010. Am J Kidney Dis 2010, 56:399-417.
18. Sargent J.A., Gotch F.A. Principles and biophysics of dialysis. Replacement of renal function by dialysis 1985, 53. Martinues Nijhoff, Hague. W. Drukker, F.M. Parsons, J.A. Maher (Eds.).
19. Lobo J.C., Mafra D., Farage N.E., et al. Increased electronegative LDL and decreased antibodies against electronegative LDL levels correlate with inflammatory markers and adhesion molecules in hemodialysed patients. Clin Chim Acta 2011, 412:1788-1792.
20. Wratten M.L., Galaris D., Tetta C., Sevanian A. Evolution of oxidative stress and inflammation during hemodialysis and their contribution to cardiovascular disease. Antioxid Redox Signal 2002, 4:935-944.
21. Vaziri N.D. Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial 2009, 22:644-651.
22. Mello A.P., da Silva I.T., Abdalla D.S., Damasceno N.R. Electronegative low-density lipoprotein: origin and impact on health and disease. Atherosclerosis 2011, 215:257-265.
23. Lobo J., Santos F., Grosso D., et al. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis. Nephron Clin Pract 2008, 108:298-304.
24. Philipp A., Kralisch S., Bachmann A., et al. Serum levels of the adipokine zinc-α2-glycoprotein are increased in chronic hemodialysis. Metab Clin Exp 2011, 60:669-672.
25. Sánchez-Quesada J.L., Benítez S., Ordóñez-Llanos J. Electronegative low-density lipoprotein. Curr Opin Lipidol 2004, 15:329-335.
26. Tai M.H., Kuo S.M., Liang H.T., et al. Modulation of angiogenic processes in cultured endothelial cells by low density lipoprotein subfractions from patients with familial hypercholesterolemia. Atherosclerosis 2006, 186:448-457.
27. Benítez S., Camacho M., Bancells C., Vila L., Sánchez-Quesada J.L., Ordónez-Llano J. Wide proinflammatory effect of electronegative low-density lipoprotein on human endothelial cells assayed by a protein array. Biochim Biophys Acta 2006, 1761:1014-1021.
28. Benítez S., Bancells C., Ordonez-Llanos J., Sanchez-Quesada J.L. Pro-inflammatory action of LDL(-) on mononuclear cells is counteracted by increased IL10 production. Biochim Biophys Acta 2007, 1771:613-622.
29. Chen H.H., Hosken B.D., Huang M., et al. Electronegative LDLs from familial hypercholesterolemic patients are physicochemically heterogeneous but uniformly proapoptotic. J Lipid Res 2007, 48:177-184.
30. Shoji T., Fukumoto M., Kimoto E., et al. Antibody to oxidized low density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney Int 2002, 62:2230-2237.
31. Shoji T., Kimoto E., Shinohara K., et al. The association of antibodies against oxidized low density lipoprotein with atherosclerosis in hemodialysis patients. Kidney Int Suppl 2003, 84:128-130.
32. Karvonen J., Paivansalo M., Kesaniemi Y.A., Horkko S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 2003, 108:2107-2112.
33. Barros M.R., Bertolami M.C., Abdalla D.S., Ferreira W.P. Identification of mildly oxidized low-density lipoprotein (electronegative LDL) and its auto-antibodies IgG in children and adolescents hypercholesterolemic offsprings. Atherosclerosis 2006, 184:103-107.
34. Grosso D.M., Ferderbar S., Wanschel A.C., Krieger M.H., Higushi M.L., Abdalla D.S. Antibodies against electronegative LDL inhibit atherosclerosis in LDLr-/- mice. Braz J Med Biol Res 2008, 41:1086-1092.
35. Gao D., Trayurn P., Bing C. Macrophage-secreted factors inhibit ZAG expression and secretion by human adipocytes. Mol Cell Endocrinol 2010, 325:135-142.
36. Gohda T., Makita Y., Shike T., et al. Identification of epistatic interaction involved in obesity using KK/Ta mouse as a type 2 diabetes model: is Zn-alpha(2) glycoprotein 1 a candidate gene for obesity?. Diabetes 2003, 52:2175-2181.
37. Rolli V., Radosavljevic M., Astier V., et al. Lipolysis is altered in MHC class 1 zinc-alpha(2)-glycoprotein deficient mice. FEBS Lett 2007, 581:394-400.
38. Yeung D.C.Y., Lam K.S.L., Wang Y., Tso A.W., Xu A. Serum zinc-α2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in Chinese subjects. J Clin Endocrinol Metab 2009, 94:2531-2536.
39. Selva D.M., Lecube A., Hernández C., et al. Lower zinc-α2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance. J Clin Endocrinol Metab 2009, 94:4499-4507.
40. Wang P., Marinan E., Renes J., Keijer J. The secretory function of adipocytes in the physiology of white adipose tissue. Cell Metab 2008, 216:3-13.
41. Wang Y., Xu A., Knight C., Xu L.Y., Cooper G.J.S. Hydroxylation and glycosylation of the four conserved lysine residues on the collagenous domain of adiponectin. J Biol Chem 2002, 277:19521-19529.
42. Marrades M.P., Martínez J.A., Moreno-Aliaga M.J. ZAG, a lipid mobilizing adipokine, is downregulated in human obesity. J Physiol Biochem 2008, 64:61-66.